GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Adamas Pharmaceuticals Inc (NAS:ADMS) » Definitions » 5-Year Yield-on-Cost %

Adamas Pharmaceuticals (Adamas Pharmaceuticals) 5-Year Yield-on-Cost % : 0.00 (As of Jun. 07, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Adamas Pharmaceuticals 5-Year Yield-on-Cost %?

Adamas Pharmaceuticals's yield on cost for the quarter that ended in Sep. 2021 was 0.00.


The historical rank and industry rank for Adamas Pharmaceuticals's 5-Year Yield-on-Cost % or its related term are showing as below:



ADMS's 5-Year Yield-on-Cost % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 2.245
* Ranked among companies with meaningful 5-Year Yield-on-Cost % only.

Competitive Comparison of Adamas Pharmaceuticals's 5-Year Yield-on-Cost %

For the Drug Manufacturers - Specialty & Generic subindustry, Adamas Pharmaceuticals's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Adamas Pharmaceuticals's 5-Year Yield-on-Cost % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Adamas Pharmaceuticals's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where Adamas Pharmaceuticals's 5-Year Yield-on-Cost % falls into.



Adamas Pharmaceuticals 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of Adamas Pharmaceuticals is calculated as

Yield-on-Cost=Dividend Yield %*(1+Dividend Growth Rate)^5

Adamas Pharmaceuticals  (NAS:ADMS) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.


Adamas Pharmaceuticals 5-Year Yield-on-Cost % Related Terms

Thank you for viewing the detailed overview of Adamas Pharmaceuticals's 5-Year Yield-on-Cost % provided by GuruFocus.com. Please click on the following links to see related term pages.


Adamas Pharmaceuticals (Adamas Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
1900 Powell Street, Suite 1000, Emeryville, CA, USA, 94608
Adamas Pharmaceuticals Inc discovers, develops, and sells therapies for chronic neurologic disorders. The company's approved/commercial product is GOCOVRI, an amantadine therapy for the treatment of levodopa-induced dyskinesia in patients with Parkinson's disease. It operates in one reportable segment: the development and commercialization of therapeutics targeting chronic disorders of the central nervous system. The company generates its revenues primarily from the United States.
Executives
Vijay Shreedhar officer: Chief Commercial Officer C/O ADAMAS PHARMACEUTICALS, INC. 1900 POWELL STREET, SUITE 1000 EMERYVILLE CA 94608
Christopher B Prentiss officer: Chief Financial Officer 1900 POWELL STREET SUITE 750 EMERYVILLE CA 94608
Anna Richo director AMGEN INC., ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320-1799
David L Mahoney director SYMANTEC CORPORATION, 20330 STEVENS CREEK BLVD., CUPERTINO CA 95014
Mardi Dier director C/O ACELYRIN, INC., 4149 LIBERTY CANYON RD., AGOURA HILLS CA 91301
William W. Ericson director, 10 percent owner 777 MARINERS ISLAND BOULEVARD, SUITE 550, SAN MATEO CA 94404
John A Macphee director C/O ADAMAS PHARMACEUTICALS, INC. 1900 POWELL ST., SUITE 750 EMERYVILLE CA 94608
Ivan M Lieberburg director 11682 EL CAMINO REAL, SUITE 320, SAN DIEGO CA 92130
Michael Bigham director 890 WINTER STREET, WALTHAM MA 02451
Martha J Demski director 7770 REGENTS ROAD SUITE 113-505, SAN DIEGO CA 92122
Neil F. Mcfarlane officer: Chief Executive Officer C/O RETROPHIN, INC., 12255 EL CAMINO REAL, SUITE 250, SAN DIEGO CA 92130
Alfred G Merriweather officer: Chief Financial Officer
Jennifer J Rhodes officer: CBO, GC & Compliance Officer C/O ADAMAS PHARMACEUTICALS INC., 1900 POWELL ST., SUITE 750, EMERYVILLE CA 94608
Gregory T Went director, officer: Chief Executive Officer C/O ADAMAS PHARMACEUTICALS, INC. 2200 POWELL ST, STE 220 EMERYVILLE CA 94608
Rajiv Patni officer: Chief Medical Officer C/O OCERA THERAPEUTICS, INC., 525 UNIVERSITY AVENUE, SUITE 610, PALO ALTO CA 94301

Adamas Pharmaceuticals (Adamas Pharmaceuticals) Headlines

From GuruFocus

Adamas Reports Second Quarter 2021 Financial Results

By Business Wire Business Wire 08-09-2021

Adamas Announces Issuance of New Patents for GOCOVRI and ADS-4101

By Business Wire Business Wire 07-22-2021